US Patent Issued to DANA-FARBER CANCER INSTITUTE on Dec. 16 for "Potent and selective covalent inhibitors of serine-arginine protein kinase (SRPK) 1 and SRPK2 and uses thereof" (Massachusetts Inventors)

ALEXANDRIA, Va., Dec. 16 -- United States Patent no. 12,497,398, issued on Dec. 16, was assigned to DANA-FARBER CANCER INSTITUTE INC. (Boston).

"Potent and selective covalent inhibitors of serine-arginine protein kinase (SRPK) 1 and SRPK2 and uses thereof" was invented by Nathanael S. Gray (Boston) and John Hatcher (Boston).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed are to compounds, compositions, and methods for treating diseases or conditions mediated by aberrant serine-arginine protein kinase (SRPK) 1 and SRPK2 activity."

The patent was filed on Oct. 5, 2021, under Application No. 18/030,181.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov...